Mesa Laboratories, Inc. MLAB · NASDAQ
$122.48 -4.12% (-$5.26)
Summary
48 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 22 USD is left as free cash.
What to watch
- Out of every 100 USD of revenue, only 1.9 USD is left as net profit.
- Operating profit covers the interest on its debt only 1.6 times.
- It earns only 3.1 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 148.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 9.3% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 34 USD
- Research and development 8.0 USD
- Sales and administration 49 USD
- Taxes and other 7.1 USD
- Net profit 1.9 USD
Net profit, industry median (Medical - Specialties) 7.5 USD
Out of every 100 USD of revenue, 1.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 0.50%
- Paid out of profit
- 75%
You receive $0.64 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 3
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $110 is 10% below today's price. 38% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Sterilization and Disinfection Control 41%
- Calibration Solutions 21%
- Biopharmaceutical Development 20%
- Clinical Genomics 18%
By region
- UNITED STATES 47%
- Other 45%
- CHINA 8.2%
Sterilization and Disinfection Control brings in 41% of revenue.
Segments in detail